Martin H. Voss, MD, and Moshe Ornstein, MD, explore non-clear cell renal cell carcinoma and the potential impact of clinical trials on the evolution of treatment approaches.
EP. 2: Extended Follow Up of KEYNOTE-B61
June 24th 2024Martin H. Voss, MD, provides an update on the extended follow-up data from the phase 2 KEYNOTE-B61 study, which investigates the efficacy and safety of combination therapy consisting of pembrolizumab and lenvatinib as a first-line treatment option for patients with advanced non-clear cell renal cell carcinoma.
EP. 3: Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC
July 2nd 2024Moshe Ornstein, MD, presents an overview of the current front-line treatment options for advanced non-clear cell renal cell carcinoma, focusing on the PAPMET regimen and the promising results from the Phase 2 study investigating the combination of nivolumab and cabozantinib.
EP. 4: STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC
July 2nd 2024Dr. Martin H. Voss provides an analysis of the recent data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, focusing on the phase 3 STELLAR trial, which evaluates the safety and efficacy of the combination therapy Zanzalintinib and nivolumab in patients with non-clear cell renal cell carcinoma.